The 11th Annual Drug Discovery for Neurodegeneration Conference 2017 is dedicated to developing new drugs to treat and prevent neurodegenerative diseases.
The 11th Annual Drug Discovery for Neurodegeneration Conference 2017 covers topics such as:
- Fundamentals of medicinal chemistry relevant to drug discovery for neurodegenerative diseases
- Challenges and opportunities in academic drug discovery
- Go-no-go criteria for preclinical development, including pharmacokinetic behavior of candidate compounds, aqueous solubility, blood-brain barrier permeability, preliminary safety, and manufacturing issues
- Newest trends in assay development and high throughput screening (HTS)
- Biologics for challenging CNS targets and strategies to optimize brain delivery
- Study design considerations for animal model experiments
- Commercialization strategies for developing science into products
- Requirements for an Investigational New Drug (IND) application
- Funding & resources for preclinical therapeutics development for neurological disorders
- Best practices for working with tech transfer offices, managing intellectual property, and the role of funding organizations
The 11th Annual Drug Discovery for Neurodegeneration Conference 2017 brings together:
- Business development and licensing professionals
- Academic and industry scientists engaged in drug discovery research for neurodegenerative disease or CNS
- Young investigators and graduate students
- Alliance management professionals